Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Promise of SGN-CD70A against NHL eclipsed by adverse events
Phillips T et al. Invest New Drugs. 2018 Aug 22. doi: 10.1007/s10637-018-0655-0.
Key clinical point: A high incidence of unexplained thrombocytopenias led to abandonment of further study of SGN-CD70A in relapsed/refractory non-Hodgkin lymphomas.
Major finding: In total, 15 of 20 patients had treatment-related thrombocytopenias; 13 of these adverse events were grade 3 or greater in severity.
Study details: A 20-patient NHL cohort of a phase 1 dose-finding, pharmacologic, safety, and preliminary efficacy trial of the antibody-drug conjugate SGN-CD70A.
Disclosures: The study was funded by Seattle Genetics. Dr. Phillips reported advisory board membership with the company, and four of the coauthors are employees of the company with equity interests.
Phillips T et al. Invest New Drugs. 2018 Aug 22. doi : 10.1007/s10637-018-0655-0.